Currently we have no closed groups active. When we have it will be announced on the website.
Forgot your password?
Forgot your password? - mail us with the e-mail you have registered with. We will then send you a new password.
Greiner Bio-One GmbH ("GBO") has informed Vigmed Holding AB (publ) ("Vigmed") of the following.
As of 3 July 2017, GBO owns 89.54 percent of all shares in Vigmed. GBO's ownership in Vigmed has increased quicker than expected since Vigmed's decision to propose a new issue of shares with preferential rights for the company's shareholders. GBO has further informed that GBO intends to continue to purchase shares in the market until GBO obtains an ownership of more than 90 percent of all shares in Vigmed. In view of GBO's current rate of acquiring Vigmed shares, it is not unlikely that GBO will reach an ownership of more than 90 percent of all shares in Vigmed in the near term.
In the event GBO reaches an ownership of more than 90 percent of all shares in Vigmed, GBO intends to initiate squeeze-out of the remaining shares in Vigmed and in connection therewith promote delisting of Vigmed's shares from Nasdaq First North.
If and when GBO reaches an ownership of more than 90 percent of all shares in Vigmed and initiates such squeeze-out of the remaining shares, GBO will be of the opinion that the rights issue will no longer be appropriate. GBO will in such case no longer support the rights issue and will not vote in favor of the rights issue at the contemplated extraordinary general meeting of Vigmed. In view of the above, it may already now be concluded that the rights issue may potentially not be implemented.
For more informationCEO Henrik Olsen, tel. +46 763-497 364Board member Georg Heftberger, tel. +43 664 884 106 83
This information was submitted for publication, through the agency of the contact persons set out above, at 8:00 a.m. CET on 4 July 2017.
Vigmed is a Swedish medical technology company whose mission is to eliminate needlestick injuries and the associated risk of cross infections with blood-borne infectious diseases by offering the market unique needle-protected products. Vigmed is headquartered in Helsingborg, Sweden. Vigmed’s share is traded on Nasdaq First North in Stockholm (ticker VIG). Remium Nordic AB is the Company’s Certified Advisor. Additional information about the company can be found on Vigmed’s website: www.vigmed.com/investor